Peer Reviewed Publications

• Barrett, J., Romero K, Rayner C, Gastonguay M., Pillai G, Tannenbaum S, Kern S, Selich M, Francisco D. A Modern Curriculum for Training Scientists in Model‐Informed Drug Development: Progress Report on FDA Grant to Train Regulatory Scientists. Clinical Pharmacology & Therapeutics. 2024: 116(2), 289–294.
• Schmidt S, Vozmediano V, Cristofoletti R, Kim S, Lin Z, de Moraes N, Azeredo F, Cical Bi, Leuenberger H, Brown JD, Jin JY, Musante CJ, Tannenbaum S, Wang Y. Requirements, expectations, challenges and opportunities associated with training the next generation of pharmacometricians. CPT: Pharmacometrics & Systems Pharmacology. 2023;12:883–888.
• Rekić D, Kerbusch‑Herben V · Någård M, Chou J, Huang J, Bradley C, Åstrand M, Tannenbaum S, Hamrén B. Pharmacokinetics of Roxadustat: A Population Analysis of 2855 Dialysis‑ and Non‑Dialysis‑Dependent Patients with Chronic Kidney Disease. Clin Pharmacokinet 2021 Jan 24.
• Tannenbaum S, den Adel M, Krauwinkel W, Meijer J, Hollestein-Havelaar A, Verheggen F, Newgreen D. Pharmacokinetics of solifenacin in pediatric populations with overactive bladder or neurogenic detrusor overactivity. Pharmacol Res Perspect 2020 Dec;8(6):e00684
• Krishnaswami S, Austin D, Della Pasqua O, Gastonguay M, Gobburu J, van der Graaf P, Ouellet D, Tannenbaum S, Visser S. MID3: Mission Impossible or Model‑Informed Drug Discovery and Development? Point‑Counterpoint Discussions on Key Challenges. Clinical Pharmacology & Therapeutics. 2020 Apr;107(4):762-772.
• Rittig S, Baka-Ostrowska M, Tøndel C, Walle JV, Kjaeer B, Passier P, Bosman B, Stroosma O, Tannenbaum S. The pharmacokinetics, safety, and tolerability of mirabegron in children and adolescents with neurogenic detrusor overactivity or idiopathic overactive bladder and development of a population pharmacokinetic model-based pediatric dose estimation. J Pediatr Urol. 2020 Feb;16(1):31.e1-31.e10
• Chaves R, Chakraborty A, Benziger D, and Tannenbaum S. Clinical and pharmacokinetic considerations for the use of daptomycin in patients with Staphylococcus aureus bacteraemia and severe renal impairment. Journal of Antimicrobial Chemotherapy 2014; 69: 200–210. https://academic.oup.com/jac/article-abstract/69/1/200/856754
• Bonate P, Strougo A, Desai A, Roy M, Yassen A, van der Walt JS, Kaibara A, Tannenbaum S. Guidelines for the Quality Control of Population Pharmacokinetic–Pharmacodynamic Analyses: an Industry Perspective. The AAPS Journal, July 2012.
• Chakraborty A, Tannenbaum S, Rordorf C, Lowe P, Floch D, Gram H, Roy S. Pharmacokinetic and Pharmacodynamic Properties of Canakinumab, a Human anti-IL-1β Monoclonal Antibody. Clinical Pharmacokinetics, 51 (6), 2012.
• Kuemmerle-Deschner JB, Ramos E, Blank N, Roesler J, Felix SD, Jung T, Stricker K, Chakraborty A, Tannenbaum S, Wright AM, Rordorf C. Canakinumab (ACZ885, a fully human IgG1 anti-IL-1β mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS). Arthritis Research and Therapy, 13(1): R34, 2011.
• Stone JA, Banfield C, Pfister M, Tannenbaum S, Allerheiligen S, Wetherington JD, Krishna R, Grasela DM. Model-based drug development survey finds pharmacometrics impacting decision making in the pharmaceutical industry. Journal of Clinical Pharmacology, 50 (9 suppl): 20S-30S, 2010.
• Lowe P, Tannenbaum S, Wu K, Lloyd P, Sims J. On setting the first dose in man: quantitating biotherapeutic drug-target binding through pharmacokinetic and pharmacodynamic models. Basic & Clinical Pharmacology & Toxicology, 106(3):195- 209, 2010.
• Lowe P, Tannenbaum S, Gautier A. Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma. British Journal of Clinical Pharmacology, 68(1): 61-76, 2009.
• Slavin R, Ferioli C, Tannenbaum S, Martin C, Blogg M, Lowe P. Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing immunoglobulin-E and decreasing pharmacokinetic concentrations. Journal of Allergy and Clinical Immunology, 123 (1), 107-113.e3, 2009.
• Tannenbaum S, Holford N, Mould D, Lee H, Peck C. Simulation of Correlated Continuous and Categorical Variables using a Single Multivariate Distribution. Journal of Pharmacokinetics and Pharmacodynamics, Volume 33 (6), 773, 2006.
• Boxenbaum H, Tannenbaum S, Oleson F, Mayersohn M. Pharmacokinetic Tricks and Traps: Drug Dosage Adjustment in Renal Failure. The Journal of Pharmacy and Pharmaceutical Sciences, 2(1), 2-4, 1999.
• Mayersohn M and Tannenbaum S. On Reclaiming Data from the Literature: Literature Data ‘R and R’ (Recovery and Reanalysis). American Journal of Pharmaceutical Education, 62(4), 363-372, 1998.
• Tannenbaum S, Boxenbaum H, Mayersohn M. Allometric Analysis of Organ Extraction Ratios. Journal of Pharmaceutical Sciences, 86 (11), 1319 -1320, 1997.

Other Publications

• Tannenbaum S, Riggs M, Horner M. Science by Numbers: Predictive Modeling in Pharmaceutical Discovery, Development, and Manufacturing. Cover article, AAPS News Magazine, Apr 2020.
• Bonate P, Tannenbaum S. Speaking into the Ether- Challenges of the Virtual Pharma Workplace. The Certara Blog, Aug 2017.
• Bonate PL, Desai A, Rizwan A, Lu Z, and Tannenbaum S. “Nonlinear Mixed Effects Modeling in Systems Pharmacology”. Book chapter in Systems Pharmacology and Pharmacodynamics. Mager, Donald E., Kimko, Holly H.C. (Eds.). Springer, 2016.
• Bruno R, Mentré F, Tannenbaum S, Wang Y, Corrigan B, and Mager D. ISoP Standards and Best Practices Committee. Clinical Pharmacology & Therapeutics (2014); 95 6, 581–582
• Pfister M, Mager D, Holford N, Tannenbaum S, Bruno R, Zhang L, Wang Y, D’Argenio D. The International Society of Pharmacometrics. Journal of Pharmacokinetics and Pharmacodynamics, 41 (1S), 3-4, 2013.
• D’Argenio DZ, Gastonguay MR, Brundage RC, Miller R, Tannenbaum SJ, Pfister M. Affiliation between the American Society of Pharmacometrics and the Journal of Pharmacokinetics and Pharmacodynamics. Journal of Pharmacokinetics and Pharmacodynamics, 39(1): 3, 2012
• Brundage R, Pfister M, D’Argenio D, Gastonguay M, Miller R, Tannenbaum S. ACoP: The Tools, Carpenters, and Architects Building the Discipline of Pharmacometrics. Journal of Clinical Pharmacology, 50 (9 suppl): 7S-8S,
• Pfister M, Brundage R, Gastonguay M, Miller R, Tannenbaum S, D’Argenio D. Defining the Future of Pharmacometrics: The American Society of Pharmacometrics. Journal of Clinical Pharmacology, 50 (9 suppl): 158S, 2010.